...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Setting a Global Example: Three Accredited Next Generation Sequencing Platforms Under One Roof

| Print |
Tuesday, 23 April 2013 09:30 (UTC + 2)

GATC Biotech logo2

Konstanz, Germany, April 23, 2013 / B3C newswire / – With official accreditation of yet another sequencing platform, GATC Biotech presents the worldwide first trio of accredited NGS platforms under one roof. After successful accreditation the technology platforms Ilumina HiSeq and Roche GS FLX, the high quality of PacBio RS sequencing has now officially been confirmed by the national accreditation body for the Federal Republic of Germany (DAkkS).

The combination of three accredited Next Generation Sequencing platforms under one roof is said to be unique globally. The Pacific Biosciences PacBio RS platform located at GATC Biotech’s headquarter has been officially accredited according to EN ISO/IEC 17025. The accreditation of PacBio RS adds an extensive variety of efficiency and quality to the pre-high-quality fleet of different platforms. Thereby, the company achieves maximum exhaustion of all Next Gen Systems available within its own laboratory.

Being Europe’s first sequencing provider to use the PacBio RS platform, GATC Biotech emphasises its position on the international sequencing market. The third accreditation within one year demonstrates the latest state-of-the-art standards in the company’s methods, technologies and data quality that are pursued by responsible staff members at all times.

As Dr. Marcus Benz, COO of GATC Biotech AG, explains:”The flexible accreditation of various platforms allows our customers to benefit from the firsthand and experienced support and to rely on an all-time audited international quality standard.”


About GATC Biotech
GATC Biotech is Europe’s leading service provider of DNA sequencing with more than 10.000 academic and industrial customers worldwide. For over two decades, we have offered sequencing and bioinformatics solutions from single samples up to large scale projects. GATC Biotech has sequenced more than 5 million samples, ten thousands of bacterial, plant and other whole genomes as well as hundreds of whole human genomes.

Having Agilent and Illumina Certified Service Provider status, GATC Biotech offers true multiplatform sequencing using all leading sequencing technologies in its own labs. In order to evaluate these immense data quantities professionally, GATC Biotech keeps its own IT farm.

Headquartered in Constance, Germany, the company houses its ISO 17025 certified Genome and Diagnostic Centre with a focus on Next and Third Generation sequencing. The European Custom Sequencing Centre located in Cologne focuses on Sanger Sequencing and serving as the logistical hub within Europe. All laboratories have highly integrated and fully automatic processing pipelines and enable full compliance with latest state-of-the-art quality standards. Since 2010, GATC Biotech has been a key supplier for the International Cancer Genome Project.

GATC Biotech´s subsidiary LifeCodexx emphasises the development of clinically validated molecular diagnostic tests and offers a risk-free alternative to common invasive examination methods such as amniocentesis.


Press Contact:

GATC Biotech AG
Lisa-Annina Quintes
Jakob-Stadler-Platz 7
78462 Konstanz
Germany
Phone: +49 (0) 7531-81604117
Fax: +49 (0) 7531-816081
Email:  This e-mail address is being protected from spambots. You need JavaScript enabled to view it This e-mail address is being protected from spambots. You need JavaScript enabled to view it